Table 3 Multivariate analysis of time to CNS metastases adjusted for non-CNS metastases as competing risk
Parameter | Hazard ratio | 95% hazard ratio confidence limits | Significance level |
|---|---|---|---|
Analysis without consideration of pCR rate | |||
 Age (continuous) | 1.001 | 0.984–1.018 | p = 0.9359 |
 Tumor size (cT3–4) (reference category: cT1–2) | 1.830 | 1.223–2.737 | p = 0.0033 |
 Node-positive disease (reference category: node-negative disease) | 2.681 | 1.710–4.205 | p < 0.0001 |
 Luminal B-like subtype (reference category: luminal A-like subtype) | 1.573 | 0.611–4.053 | p = 0.3478 |
 HER2-positive subtype (reference category: luminal A-like subtype) | 3.357 | 1.673–6.736 | p = 0.0007 |
 Triple-negative subtype (reference category: luminal A-like subtype) | 5.569 | 2.882–10.758 | p < 0.0001 |
Analysis with consideration of pCR rate | |||
 Age (continuous) | 0.999 | 0.981–1.016 | p = 0.8813 |
 Tumor size (cT3–4) (reference category: cT1–2) | 1.626 | 1.075–2.458 | p = 0.0213 |
 Node-positive disease (reference category: node-negative disease) | 2.574 | 1.641–4.037 | p < 0.0001 |
 Luminal B-like subtype (reference category: luminal A-like subtype) | 1.617 | 0.627–4.171 | p = 0.3200 |
 HER2-positive subtype (reference category: luminal A-like subtype) | 3.804 | 1.894–7.639 | p = 0.0002 |
 Triple-negative subtype (reference category: luminal A-like subtype) | 6.384 | 3.277–12.440 | p < 0.0001 |
 No pCR after neoadjuvant chemotherapy (reference category: pCR after neoadjuvant chemotherapy) | 2.294 | 1.324–3.973 | p = 0.0031 |